Default

Allergy and immunology

Anaesthesia

Basic research

Cardiovascular medicine

Complementary medicine and alternative therapies

Critical care / intensive care

Dentistry / oral medicine

Dermatology

Emergency medicine

Endocrinology

Epidemiology

Ethics

Evidence-based medicine

Gastroenterology

Genetics

Geriatric medicine / aging

Haematology / blood transfusion

Health economics

Health policy

History of medicine

Infectious diseases

Internal medicine

Laboratory medicine

Medical education

Medical informatics

Neurology

Nursing

Nutrition and metabolism

Obstetrics and gynaecology

Occupational and environmental medicine

Oncology

Ophthalmology

Organisation of health care

Otolaryngology / head and neck surgery

Paediatrics

Palliative care

Pathology

Patient-physician relationship

Pharmacology and therapeutics

Primary care, family medicine

Psychiatry and psychotherapy

Psychosomatics

Public health

Quality of care

Radiology

Rehabilitation medicine

Renal medicine

Respiratory medicine

Rheumatology

Sexual medicine

Sports medicine

Statistics and research methods

Surgery

Transplantation

Travel medicine

Urology

Ops! No article found. Reset filter

The SilenT AtRial FIBrillation (STAR-FIB) study programme – design and rationale

Original article
Nozica N, Lam A, Goulouti E, Elchinova E, Spirito A, Branca M, Servatius H, Noti F, Seiler J, Baldinger SH, Haeberlin A, de Marchi SF, Asatryan B, Rodondi N, Donzé J, Aujesky D, Tanner H, Reichlin T, Jüni P, Roten L
Swiss Med Wkly. 2021;151:w20421

Anticoagulation of patients with screen-detected atrial fibrillation may prevent ischaemic strokes. The STAR-FIB study programme aims to determine the age- and sex-specific prevalence of silent atrial fibrillation and to develop a clinical prediction model to identify patients at risk of undiagnosed atrial fibrillation in a hospitalised patient population.

Association of in-hospital multimorbidity with healthcare outcomes in Swiss medical inpatients

Original article
Müller M, Huembelin M, Baechli C, Wagner U, Schuetz P, Mueller B, Kutz A
Swiss Med Wkly. 2021;151:w20405

Multimorbidity poses a worldwide health- and socio-economic challenge, exacerbated by changing demographics. The association of multimorbidity with healthcare outcomes in hospitalised medical inpatients remains incompletely understood. This cross-sectional study analysed Swiss hospital discharge records from 2012 to 2017. Multimorbidity was highly prevalent in medical inpatients and had a relevant association with poor healthcare outcomes.

Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis

Review article: Medical guidelines
Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, Bacher VU, Bode P, Cavalli A, Concoluci A, Dirnhofer S, Djerbi N, Dobner SW, Fehr T, Garofalo M, Gaspert A, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pazhenkottil A, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Théaudin M, Treglia G, Tzankov A, Vetter F, Zweier M, Gerber B
Swiss Med Wkly. 2020;150:w20364

These are the Swiss Amyloidosis Network recommendations which focus on diagnostic work-up and treatment of AL-amyloidosis. One aim of this meeting was to establish a consensus guideline regarding the diagnostic work-up and the treatment recommendations for systemic amyloidosis tailored to the Swiss health care system.

Mortality prediction in acute heart failure: scores or biomarkers?

Review article: Biomedical intelligence
Wussler D, Michou E, Belkin M, Kozhuharov N, Diebold M, Gualandro DM, Breidthardt T, Mueller C
Swiss Med Wkly. 2020;150:w20320

Acute heart failure is a complex and heterogeneous syndrome not only associated with a concerning rise in incidence, but also with still unacceptably high rates of mortality and morbidity. As this dismal outcome is at least in part due to a mismatch between the severity of acute heart failure and the intensity of its management, both in-hospital and immediately after discharge, early and accurate risk prediction could contribute to more effective, risk-adjusted management.

Iron overload associated symptoms and laboratory changes in the Swiss Haemochromatosis Cohort – when a clinician should become attentive

Original article
Kölmel S, Nowak A, Krayenbuehl PA
Swiss Med Wkly. 2020;150:w20294

Elevated ALT levels and metacarpophalangeal arthropathy remained independently associated with elevated ferritin levels in patients with haemochromatosis and should prompt clinicians to consider iron overload in patients with hereditary haemochromatosis.

Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis

Original article
Gregoriano C, Koch D, Haubitz S, Conen A, Fux CA, Mueller B, Bernasconi L, Hammerer-Lercher A, Oberle M, Burgermeister S, Reiter H, Kutz A, Schuetz P
Swiss Med Wkly. 2020;150:w20316

This analysis provides insights into the first consecutively hospitalised patients with confirmed COVID-19 at a Swiss tertiary care hospital during the initial period of the pandemic. Markers of disease progression such as inflammatory markers, markers for shock and impaired respiratory function provided the most prognostic information regarding severe COVID-19 progression in this sample.

Characteristics, comorbidities, 30-day outcome and in-hospital mortality of patients hospitalised with COVID-19 in a Swiss area – a retrospective cohort study

Original article
Pellaud C, Grandmaison G, Pham Huu Thien HP, Baumberger M, Carrel G, Ksouri H, Erard V, Chuard C, Hayoz D, Sridharan G
Swiss Med Wkly. 2020;150:w20314

The authors report the first cohort of Swiss patients hospitalised with COVID-19. Thirty days after onset of the symptoms, 60% had returned home. Among them, 63% still presented symptoms.

Effect of guideline revisions by the Swiss Society of Hypertension on blood pressure control in hypertensive patients from primary care

Original article
Giezendanner S, Tschudi P, Leuppi J, Dieterle T, Zeller A
Swiss Med Wkly. 2020;150:w20279

The 2009 guideline change in high-risk patients was associated with a reduction in systolic office blood pressure together with an increase in pharmacological combination therapy. These results highlight primary care physicians’ efforts to implement blood pressure guidelines. Further, blood pressure goal attainment was more likely to be achieved in later follow-up visits.

Supporting health professionals after an adverse event in Swiss hospitals: a cross-sectional study

Original article
Reiser Crelier F, Schwappach D, Schwendimann R
Swiss Med Wkly. 2020;150:w20278

In Swiss hospitals, second victim support is generally prevalent, but often in an unstructured way. This lack of methodology increases the risk that, following adverse events, both the quantity and quality of support provided to health professionals will be insufficient. A firm commitment on the part of institutional leaders to implement related policies could foster the adoption of high-quality second victim guidelines in Swiss hospitals.

Oral antibiotic therapy in people who inject drugs (PWID) with bacteraemia

Review article: Biomedical intelligence
Martinez AE, Scheidegger C, Bättig V, Erb S
Swiss Med Wkly. 2020;150:w20259

Treatment of bacteraemia in people who inject drugs remains very complex, and an interdisciplinary approach is essential in order to select the best therapy for this vulnerable group of patients.

Verpassen Sie keinen Artikel!

close